Landscapes / Targets
LAG-3
14 drugs act on LAG-3, in 36 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs14
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
BMS-986213not checked |
— |
Bristol Myers Squibb · Public BMY |
On the market | 26 May 2029Phase 4 trial completes | |
| Next date | 26 May 2029 · Phase 4 trial completes | ||||
| Also tested for | Melanoma, Cancer and 2 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Bristol Myers Squibb · Public BMY |
Approved | 25 Aug 2029Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 25 Aug 2029 · Phase 2 trial completes | ||||
| Also tested for | Melanoma, Cancer and 1 more | ||||
| Open drug page | |||||
LAG-3 antibody |
Regeneron · Public REGN |
Phase 3 | 15 Jan 2027Phase 3 trial completes | ||
| Next date | 15 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Melanoma, Non-small Cell Lung Cancer and 14 more | ||||
| Open drug page | |||||
Soluble LAG-3 protein (immune activator) |
Phase 3 | Jun 2027Phase 3 trial completes | |||
| Next date | Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | ||||
| Open drug page | |||||
Monoclonal antibody |
Merck & Co. · Public MRK |
Phase 3 | 4 Aug 2043Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 4 Aug 2043 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumors, Hematologic Malignancies | ||||
| Open drug page | |||||
— |
Akeso · Public 9926.HK |
Phase 1/2 | Dec 2026Phase 1/2 trial completes | ||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Classic Hodgkin Lymphoma, Non-small Cell Lung Cancer Stage IIIB/IV and 3 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Roche · Public ROG.SW |
Phase 2 | 31 Dec 2026Phase 2 trial completes | ||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Solid Tumors, Metastatic Melanoma and 4 more | ||||
| Open drug page | |||||
Artificial immunoglobulin |
Phase 1/2 | — | |||
| How it works | An antibody | ||||
| Also tested for | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | ||||
| Open drug page | |||||
— |
Henlius · Public 2696.HK |
Phase 2 | — | ||
| Also tested for | NSCLC Stage IV | ||||
| Open drug page | |||||
— |
Phase 1 | Nov 2026soonPhase 1 trial completes | |||
| Next date | Nov 2026 · Phase 1 trial completes | ||||
| Also tested for | Advanced Cancers | ||||
| Open drug page | |||||
— |
Phase 1 | 1 Mar 2027Phase 1 trial completes | |||
| Next date | 1 Mar 2027 · Phase 1 trial completes | ||||
| Also tested for | Neoplasms | ||||
| Open drug page | |||||
— |
Akeso · Public 9926.HK |
Phase 1 | May 2027Phase 1 trial completes | ||
| Next date | May 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Malignant Tumors | ||||
| Open drug page | |||||
— |
3SBio · Public 1530.HK |
Phase 1 | 30 Sep 2027Phase 1 trial completes | ||
| Next date | 30 Sep 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Malignant Tumors | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 13 of 14 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026